Promising Results from Ji Xing Pharmaceuticals' Etripamil Study
In a notable development in cardiovascular medicine, Milestone Pharmaceuticals Inc. has praised its partner, Ji Xing Pharmaceuticals Ltd., for publicly announcing encouraging topline results from a Phase 3 clinical trial of etripamil nasal spray. This trial was conducted at multiple centers across China and aimed to evaluate the safety and efficacy of etripamil in treating paroxysmal supraventricular tachycardia (PSVT). The findings are consistent with earlier studies carried out by Milestone in North America and Europe.
Success of the Phase 3 Trial
The Phase 3 trial, designated as JX02002, involved 500 patients and successfully met its primary endpoint. Analysis using the Kaplan Meier method revealed that a statistically significant higher percentage of patients treated with etripamil converted from PSVT to normal sinus rhythm within 30 minutes compared to those who received a placebo (40.5% vs. 15.9%, respectively). This effectiveness was further supported by additional statistically significant results at various timepoints following self-administration of the treatment.
Safety Profile and Implications of Etripamil
Ji Xing reported that both treatment groups had comparable rates of treatment-emergent adverse events, with no serious adverse effects associated with etripamil. These safety and tolerability findings align well with results from previous trials, reinforcing the growing evidence of etripamil's reliability. This pivotal study adds positively to the global development program, which has included over 2,000 unique patients treated with etripamil, thereby enhancing its profile in the cardiovascular therapeutics landscape.
Statement from Joseph Oliveto
Joseph Oliveto, the President and CEO of Milestone Pharmaceuticals, shared his excitement about Ji Xing's successful completion of this extensive Phase 3 trial. “We are proud to partner with Ji Xing as they advance etripamil closer to regulatory approval in China, offering hope to millions facing challenges related to PSVT,” he remarked.
Details of the Licensing Agreement
Under a strategic licensing agreement established on May 21, 2021, Milestone has granted Ji Xing exclusive rights to develop and potentially commercialize etripamil for PSVT in Greater China. This agreement provided Milestone with an upfront cash payment of $15 million, along with a $5 million investment from RTW Investments, LP. Additionally, Milestone stands to receive up to $107.5 million in milestone payments and future royalties based on etripamil’s sales within Greater China.
Understanding PSVT and Its Effects
In the United States, around two million individuals are diagnosed with PSVT, a condition that causes rapid heartbeats, sometimes exceeding 150 to 200 beats per minute. These episodes can occur unexpectedly and last for prolonged periods. Symptoms often include debilitating palpitations, dizziness, and shortness of breath, significantly impacting the daily lives and mental well-being of those affected. Many patients find themselves frustrated by the limited effective treatment options available, often turning to emergency departments for management.
How Etripamil Works
Etripamil, Milestone's flagship investigational product, is a nasal spray that delivers a novel calcium channel blocker aimed at managing rapid heart rhythm disturbances like PSVT and atrial fibrillation with rapid ventricular rates. The self-administered nature of etripamil highlights its appeal as a convenient, on-the-spot treatment, empowering patients to take greater control over their symptoms. With extensive clinical trials supporting its efficacy, etripamil is poised to revolutionize patient self-management in the future.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., listed on Nasdaq under the ticker MIST, is committed to developing innovative cardiovascular solutions that significantly improve the lives of individuals facing serious heart conditions. With a strong focus on addressing unmet patient needs, Milestone continues to pave new therapeutic pathways aimed at enabling patients to take a more active role in managing their health.
Frequently Asked Questions
What were the primary results of the JX02002 Phase 3 trial?
The trial showed that patients using etripamil had a significantly higher rate of conversion from PSVT to sinus rhythm within 30 minutes compared to those in the placebo group.
What is the potential market for etripamil in China?
If regulatory approval is granted, etripamil could be a groundbreaking treatment for the millions suffering from PSVT in Greater China.
How does etripamil function as a treatment?
Etripamil is a self-administered nasal spray that acts as a calcium channel blocker, effectively helping to manage episodes of rapid heart rate conditions.
What safety data has been reported regarding etripamil?
The latest trial indicated that etripamil's safety profile was consistent with previous studies, with no significant adverse events reported among users.
Who can provide more information about Milestone Pharmaceuticals?
For further inquiries, please contact Kim Fox at Milestone Pharmaceuticals via email at kfox@milestonepharma.com.
